CN1283319C - Tumor vaccine constituting method by combining dendritic cell multiplication and chemotaxis factor and suicide gene - Google Patents
Tumor vaccine constituting method by combining dendritic cell multiplication and chemotaxis factor and suicide gene Download PDFInfo
- Publication number
- CN1283319C CN1283319C CN 01142078 CN01142078A CN1283319C CN 1283319 C CN1283319 C CN 1283319C CN 01142078 CN01142078 CN 01142078 CN 01142078 A CN01142078 A CN 01142078A CN 1283319 C CN1283319 C CN 1283319C
- Authority
- CN
- China
- Prior art keywords
- cell
- mcf
- tumor vaccine
- tumor
- suicide gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Abstract
The present invention relates to a new method of combining DC immune functions for tumor immunotherapy, which aims at the characteristics that the proliferation and the differentiation of DC are influenced by FL; antigen presentation is reinforced by phagocytizing apoptotic bodies; TK is connected with FL by IRES; MCF-7 is transfected for obtaining a positive cell clone for expressing the TK and the FL. A DC cell is used as an antigenic carrier; TK suicide gene therapy is used as an approach for providing an antigen; the FL is used as a factor for changing a DC survival microenvironment; immunotherapy and gene therapy are combined to form a multielement tumour vaccine for providing a new approach for comprehensively resisting tumors.
Description
The present invention relates to a kind of cytokine and suicide gene synergism of utilizing, and transfer the method for immunity of organisms killing tumor cells by dendritic cell (DC) jointly.
Along with arrival of new century, medical research develops in depth, but how to effect a radical cure the difficult problem that tumor is still the puzzlement medical investigator.Along with medical model to the expansion that is " polynary-whole-comprehensive ", tumor treatment has proceeded to the Biotherapeutics stage of immunity, cytokine, gene therapy etc. from traditional operation, radiotherapy, chemotherapy, and becomes present medical worker's main research field.Tumor trace back to molecular level, it is all multifactor to have related in gene mutation, DNA damage, cell division and the atomization in signal transduction variation and the defence system antioxidant level reduction etc., but the co-channel of its development is in the microenvironment of tumor cell and effector lymphocyte's coexistence, tumor cell is expressed weak because of specific antigen or lacked costimulating factor can not the activation effect cell, thereby escapes down from immune supervision and to become the neoplasm of indeterminate growth.In tumor and in infecting, immune system is being regulated and control advancing of disease and is being lapsed to, and wherein the function of T cell is in occupation of leading position, and therefore, effectively activated T cell is the shortcut of treatment.Between tumprigenicity cell and T cells, need sole duty to offer antigenic cell.
(dendritic cell DC) becomes the upsurge that people study to dendritic cell once more, comes from the antigen presentation function of having found that it is powerful.Because of its full-time submission antigen, stimulate in the body initial
T cell and in the inducing of immunne response, occupy unique status.Data shows simultaneously, thereby dendritic cell can be strengthened antigenic submission activated T cell by engulfing apoptotic body.Its antineoplastic mechanism is to compensate antigen signals and the costimulating factor that lacks in the tumor-escape mechanism, and the maturation of amplification in vitro method has represented its good prospects for application.Dendritic cell antineoplastic characteristics are that it can absorb all kinds of antigens, utilize MHC molecule, costimulating factor and the adhesion molecule etc. of himself high expressed, two stimulus signals are passed to the T cell, thereby inducing specific CTL plays a role to amplify immunological effect.Therefore, the someone claims that dendritic cell is the bridge of frame between CTL and tumor cell.According to tumor cell immune evasion mechanism, comprise: 1. the external DC of being carried on of cellularity tumor antigen or tumor antigen peptide based on the antitumor strategy of DC cell; 2. the tumor antigen encoding gene imports DC or tumor cell mRNA stimulated in vitro DC; 3. the fusant of tumor cell and DC is fed back lotus tumor host or with the external impact sensitization of specific antibody DC, and observe good anti-tumor effect.DC feeds back therapy and has tried out the lymphoma in Fei Hejiejinshi B, the treatment of late tumor patients such as melanoma.And the anti-tumor effect of DC vaccine obviously is better than the GMTV vaccine and preparation is simple relatively, and technology and the method for the external a large amount of amplification DC that established at present.
The gene therapy of tumor makes people see a gleam of hope of radical cure tumor.Its strategy be will tumor be had direct or indirect lethal effect gene in carrier changes body over to, express killing tumor cells with its position at tumor growth.The suicide gene therapy also claims the medicaments insensitive therapy, its part that induces one is not only to be easy to control, the more important thing is energy direct killing tumor cell, and have " bystander effect ", its possibility mechanism is relevant with three factors at least: 1. the iuntercellular slit connects and apoptosis.2. immunoreation.3. the necrosis of tumor vascular endothelial cell.And it can make body produce the tumour-specific immunity by " inoculation effect ".The suicide gene therapy can produce long term effect, and concrete implementer is still powerful immune system in the body, and the two organic combination can be brought into play strong effect in tumor treatment.Uniting third guanosine (GCV) with herpes simplex virus thymidine kinase (HSV-TK) gene transfer is that HSV-GCV/TK is that the suicide gene of representative promptly is a big class wherein.The U.S. has treated the scheme of malignant tumor by several HSV-TK/GCV at present.
The cytokine gene therapy is by transferring the gene therapy of immunity of organisms killing tumor cells.Carried out the gene transfection treatment of cytokine medical worker at the end of last century, but simple cytokine therapy brings breakthrough for the radical cure tumor, people more are with it and other means use in conjunction at present.On the one hand by the direct killing effect of some cytokine to tumor; On the one hand by excretory cytokine regulating action to immunocytes such as CTL, APC in microenvironment.FL is a kind of cytokine that acts on early stage hemopoietic progenitor cell.Confirm at present the quantity that it can be by improving DC prerequisite cell and prolonged its time-to-live, down collaborative in other cytokine, making the DC directed differentiation is powerful antigen presenting cell, and FL itself has the anticancer ability of mediation immune system.The present invention gets involved FL in the combination of DC immunotherapy and TK suicide gene therapy, be that the FL of MCF-7/TK-FL emiocytosis has following effect: 1. bring into play the anticarcinogenic effect of himself, change the microenvironment of tumor.Can to DC induce the generation effect, strengthen antigenic submission.Along with the research to FL is goed deep into, it is found that FL is a kind of than the more potential mobilization agent of G-CSF, if when inducing DC, add FL with the peripheral blood of leukemia patient self, may be significant to quantity and its time-to-live of prolongation of improving the CD34+ cell.
In a word, immunomodulating is the basis of oncobiology therapy.The transfer body produces strong anti tumor immune response and is only the road that effects a permanent cure.Dendritic cell is full-time antigen presenting cell, and gene transfer provides some means of the microenvironment that changes its effect.Studies show that the principle of the long term effect of HSV-TK/GCV promptly is after the antigen of killed oncocyte is handled by APC, to offer the T cell, thereby produced the tumour-specific immunity.And the submission antigen function of DC can be strengthened by engulfing apoptotic body really, so the dendritic cell vaccination therapy is combined with TK suicide gene therapy, makes the TK gene therapy bring into play the anti-tumor of its lethal effect on the one hand; On the one hand apoptotic body can be DC and engulfs among the bystander effect, thereby further strengthens antigenic submission.With the means of FL as change DC existence microenvironment, make DC fully-developed under the effect that is subjected to various stimulating factors simultaneously, intravital differentiation pathway and external amplification are induced with a lot of promptings.
The Comprehensive Treatment approach of tumor has been showed fine prospect to people, complies with the research boom of DC, immunotherapy and gene therapy is combined can have good anti-tumor effect.
Content of the present invention is unexposed to be delivered, and those skilled in the art can not obtain using method of the present invention according to existing technology deduction as not spending creative work at all.
The purpose of this invention is to provide a kind of antineoplastic method, so that can be widely used in basis and clinical based on the Biotherapeutics of DC cell.
The used DC cell of the present invention mainly selects umbilical blood and peripheral blood as the source that induces.Adopt immunomagnetic beads method acquisition umbilical blood CD34+ cell and peripheral blood to go B to remove the T mononuclear cell, induce DC with GM-CSF, IL-4, FL, different cytokine compatibilities such as TNF-α, SCF respectively.
The used MCF-7 of the present invention is the breast carcinoma cell strain of a kind of high expressed adenocarcinoma common antigen MUC-1, often is used as the target cell of anti-tumor experimentation.HSV-TK/GCV is as system the most frequently used in the suicide gene therapy, it to look on effect noticeable, it is combined with immunotherapy, be to make it move towards clinical transition sooner.FL is a kind of cytokine that acts on early stage hematopoietic cell, it is the part of tyrosine kinase Flt-3/flk-2 receptor, can be by improving DC prerequisite cell quantity and prolonging a large amount of DC of acquisition of its time-to-live, directed differentiation is powerful antigen presenting cell under other cytokine effect.
The experimental research of the anti-tumor of dendritic cell associating MCF-7/TK-FL tumor vaccine among the present invention, with solid tumor MCF-7 is target cell, based on dendritic cell, comprehensive TK suicide gene therapy, FL cytokine therapy, the immunologic function that makes DC is strengthened because of engulfing apoptotic body and obtaining in the microenvironment support of FL, thereby has expanded the application space of DC treatment.
With embodiment the present invention is further elaborated below.
Embodiment 1.FL on DC induces collaborative stimulation and the DC cell to the proliferation function of T cell.
One, method
The separation and purification of 1 immunomagnetic beads method umbilical blood CD34+ cell.
2 immunomagnetic beads method peripheral bloods go B to go the monocytic separation and purification of T.
The inducing of 3 dendritic cell, purification system.
1) umbilical blood CD34+ cell, peripheral blood go B to go the T mononuclear cell to be inoculated in 12 orifice plates with 5*103/ml, every hole 1ml.
2) cultivating system IMDM contains volume fraction and is 12.5% the HS and GM-CSF (40ng/ml), TNF-a (50U/ml), SCF (100ng/ml), FL (40ng/ml) and the IL-4 (400U/ml, 1000U/ml) of FCS, 5*107mol/L hydrocortisone and various combination.37 degree, volume fraction are to cultivate under the 5%CO2 condition, and half amount is changed liquid weekly.
3) cell culture to the 8 days is standby, adopts magnetic activated cell (sorting) during the DC purification.
A) flow cytometer detects the cell phenotype of CD1a, HLA-DR, CD80.
B) state of the DC cell of electronic microscope photos separate sources.
C) detect the breeder reaction that DC stimulates the T cell with cobalt 60 irradiations flicker numeration instrument.
Two, result
1.GM-CSF, the combination of TNF-a, SCF and FL cytokine can be by CD34
+Cell induces DC, and phenotype detects CD1a
+Cell proportion increases to 67.6% ± 2.1%, and wherein FL shows the obvious synergistic stimulation to inducing of DC.
2.GM-CSF, the combination of cytokines of IL-4 can go B to go the T mononuclear cell to induce DC by peripheral blood, the IL-4 consumption is 1000U/ml, the CD1a cell is 21.8% ± 0.32%; IL-4 is 400U/ml when following, CD1a
+Cell only accounts for 3.3% ± 0.16%, illustrates to induce CD1a
+The ratio of cell is relevant with the consumption of IL-4, and prompting IL-4 plays an important role to the macrophage differentiation to suppressing mononuclear cell.
3. umbilical blood CD34
+Cell and peripheral blood go B to remove DC no significant difference on form, phenotype of T cells of monocytic origin, and both all have the effect of clear and definite stimulation T cell proliferation, can be selection of clinical usefulness from now on.
Embodiment 2. is transfected into MCF-7 and the MCF-7/TK cell lethal effect to GCV with HyHSV/TK.
One, method
1. liposome-mediated tgls (+) Hy-TK changes incasing cells PA317 over to.
2. viral supernatant titer determination
3. retroviral supernatant transfection MCF-7 cell
4.PCR the integration of the heavy TK gene of method identification of M CF-7/TK cell.
The PCR reaction system:
Each 1ul of PCR primer and template; Taq enzyme 0.3ul; Buffer 5ul; Dntp 4ul; Add water to the 50ul system, pre-degeneration 94 degree 5min---degeneration 94 degree 1min---annealing 60 degree 1min---extend 72 degree 1min, 30 circulations, and 1% agarose gel electrophoresis is checked the PCR product.
5.MCF-7/TK the Southern blot of genomic DNA
6.MTT method detects the lethal effect of GCV to MCF-7/TK
7.Trypan the method for dying of refusing blue detects the bystander effect in the MCF-7/TK GCV system
8.MCF-7/TK the mensuration of GCV systems radiate sensitivity.
9.FACS method detects the apoptosis phenomenon in the MCF-7/TK GCV system.
10.DC stimulate the T cell proliferation experiment.
Two, result
1. with retroviral tgLS (+) TK transfection MCF-7, killing experiments in vitro shows that the MCF-7/TK cell can effectively be killed and wounded under the GCV effect, and the dose concentration dependency is arranged;
There is the bystander effect in the MCF-7/TK+GCV system.
2.MCF-7/TK+GCV there is radiosensitivity in system, radiotherapy can improve the kill rate of GCV.
3.MCF-7/TK+GCV the MCF-7/TK in the system is through the GCV effect or be aided with irradiation and have clear and definite apoptosis phenomenon to exist, DC and apoptotic cell are educated the ability raising that the back stimulates the T cell proliferation altogether.These results have supported the mechanism that the bystander effect is taken place on the one hand; One side illustrates that the apoptotic body of apoptosis phenomenon initiation can be DC and engulfs, thereby strengthens DC to antigenic submission, stimulates the propagation of T cell.
The structure of embodiment 3.PIRES-TK-FL carrier and FL are to the influence of DC propagation.
One, method
1.PIRES-TK-FL Construction of eukaryotic.
2. liposome-mediated PIRES-TK-FL eukaryon expression plasmid transfection MCF-7 cell.
3.PCR the integration of TK, FL in the method identification of M CF-7/TK-FL cell genomic dna.
The pcr amplification system of the DNA of MCF-7/TK-FL cell:
Buffer 5ul, dNTP4ul, template 5ul, MgCl24ul, two kinds of primer sum 1ul, Taq enzyme 0.2ul, sterilized water polishing are to 50ul, and pre-degeneration 94 degree 5min-degeneration 94 degree 1min---annealing 60 degree 1min-extend 72 degree 1min, 30 circulations.
TK gene fragment amplification method is the same.
4.MCF-7/TK-FL the Southern blot of genomic DNA identifies.
5.Western blot detects the FL albumen in the MCF-7/TK-FL culture supernatant.
6.ELISA method is to the quantitative assay of FL in the MCF-7/TK-FL cells and supernatant.
7.MCF-7/TK-FL cells and supernatant stimulates people CD34+ cell proliferation experiment.
8. colonies culture detects the activity of FL in the MCF-7/TK-FL cells and supernatant.
9.MCF-7/TK-FL the effect of culture supernatant in DC induces.
10. cobalt 60 irradiation flicker scale of notation detect the apoptosis of MCF-7/TK-FL cell.
Two, result
1. make up people PIRES/TK-FL eukaryon expression plasmid, lipid lifting manipulation success transfection MCF-7 cell, the expression of the protein level of FL is arranged in the supernatant, and ELISA quantitatively is 15.7ng/ml/105cells/4day, measures this FL biologically active through CD34+ cell culture method and colony forming method.
2.MCF-7/TK-FL cells and supernatant is to the collaborative stimulation of having induced of DC, the CD1a+ cells ratio rises to 8.17% by 4.12% of matched group, illustrates that FL works as the differentiation and maturation of microenvironment factor pair DC.
3.MCF-7/TK-FL cell can or be aided with apoptosis-induced phenomenon under cobalt 60 irradiations in the GCV effect equally, can these means as enhancing DC immunologic function.
Claims (6)
1. the tumor vaccine that the combining dendritic cell multiplication and chemotaxis factor suicide gene makes up is characterized in that making up PIRES-TK-FL carrier for expression of eukaryon and transfection MCF-7 cell, thereby obtains this tumor vaccine MCF-7/TK-FL.
2. use the tumor vaccine that suicide gene makes up for one kind, it is characterized in that changing tgls (+) Hy-TK over to incasing cells PA317,, thereby obtain this tumor vaccine MCF-7/TK with its retroviral supernatant transfection MCF-7 cell.
3. a method that makes up combining dendritic cell multiplication and chemotaxis factor suicide gene tumor vaccine is characterized in that making up PIRES-TK-FL carrier for expression of eukaryon and transfection MCF-7 cell, thereby obtains this tumor vaccine MCF-7/TK-FL.
4. use the method that suicide gene makes up tumor vaccine for one kind, it is characterized in that changing tgls (+) Hy-TK over to incasing cells PA317,, thereby obtain this tumor vaccine MCF-7/TK with its retroviral supernatant transfection MCF-7 cell.
5. tumor vaccine according to claim 1 and 2, but it is characterized in that the tumor vaccine that obtains cell death inducing under the effect of irradiation or GCV, the ability that improves stimulation T cell proliferation after educating altogether, DC and apoptotic cell is arranged.
6. according to claim 3 or 4 described methods, but it is characterized in that tumor vaccine cell death inducing under the effect of irradiation or GCV of obtaining, the ability that improves stimulation T cell proliferation is arranged after DC and apoptotic cell are educated altogether.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01142078 CN1283319C (en) | 2001-09-11 | 2001-09-11 | Tumor vaccine constituting method by combining dendritic cell multiplication and chemotaxis factor and suicide gene |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01142078 CN1283319C (en) | 2001-09-11 | 2001-09-11 | Tumor vaccine constituting method by combining dendritic cell multiplication and chemotaxis factor and suicide gene |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1344566A CN1344566A (en) | 2002-04-17 |
| CN1283319C true CN1283319C (en) | 2006-11-08 |
Family
ID=4676609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 01142078 Expired - Lifetime CN1283319C (en) | 2001-09-11 | 2001-09-11 | Tumor vaccine constituting method by combining dendritic cell multiplication and chemotaxis factor and suicide gene |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1283319C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11975365B2 (en) | 2015-07-16 | 2024-05-07 | Sortera Technologies, Inc. | Computer program product for classifying materials |
-
2001
- 2001-09-11 CN CN 01142078 patent/CN1283319C/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11975365B2 (en) | 2015-07-16 | 2024-05-07 | Sortera Technologies, Inc. | Computer program product for classifying materials |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1344566A (en) | 2002-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hladíková et al. | Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8+ T cells | |
| Baxevanis et al. | Compromised anti‐tumor responses in tumor necrosis factor‐α knockout mice | |
| Finke et al. | Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+ CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene | |
| Watchmaker et al. | Independent regulation of chemokine responsiveness and cytolytic function versus CD8+ T cell expansion by dendritic cells | |
| AU2019240684A1 (en) | Improved methods of cell culture for adoptive cell therapy | |
| US9345754B2 (en) | Allogeneic tumor therapeutic agent, a vaccine using allogeneic tumor cells for the therapeutic treatment of tumor diseases, and a method for the making of such a vaccine, and transfected human tumor cells for use as a vaccine | |
| Lapteva et al. | Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity | |
| Chang et al. | Soypeptide lunasin in cytokine immunotherapy for lymphoma | |
| CN104087592A (en) | AFP[158-166] specific TCR gene, its transgenic T cell, and in-vitro proliferation method and use of transgenic T cell | |
| Zeng et al. | Exhausted T cells and epigenetic status | |
| US11357804B2 (en) | Application of oncolytic viruses as immunostimulants for treatment of tumors and/or cancers | |
| Geary et al. | Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN | |
| Smits et al. | The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells | |
| Xiao et al. | Local administration of TLR ligands rescues the function of tumor-infiltrating CD8 T cells and enhances the antitumor effect of lentivector immunization | |
| Huang et al. | Targeting glutamine metabolism to enhance immunoprevention of EGFR‐driven lung cancer | |
| US9072690B2 (en) | Tumor antigen proteins or genes of polo-like kinase 1 | |
| Kravtsov et al. | Roles of CD4+ T cells as mediators of antitumor immunity | |
| Tan et al. | The therapeutic effect of cytokine-induced killer cells on pancreatic cancer enhanced by dendritic cells pulsed with K-ras mutant peptide | |
| van Eck van der Sluijs et al. | Clinically applicable CD34+-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses | |
| Freitas-Silva et al. | Dendritic cell-based approaches in the fight against diseases | |
| Seif et al. | Long-term protection from syngeneic acute lymphoblastic leukemia by CpG ODN-mediated stimulation of innate and adaptive immune responses | |
| WO2023123195A1 (en) | Engineered immune cell target gene of which can be regulated, preparation method therefor, and use thereof | |
| Staege et al. | Functional and molecular characterization of interleukin‐2 transgenic Ewing tumor cells for in vivo immunotherapy | |
| CN1283319C (en) | Tumor vaccine constituting method by combining dendritic cell multiplication and chemotaxis factor and suicide gene | |
| CN116574679A (en) | Preparation method and application of specific NK cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20020417 Assignee: SOUTH CHINA CENTER FOR STEM CELL BIOLOGY AND REGENERATIVE MEDICINE OF ACADEMY OF MILITARY MEDICAL SCIENCES Assignor: Inst. of Field Blood Transfusion, Academy of Military Medical Sciences, PLA Contract record no.: 2015990000123 Denomination of invention: Tumor vaccine constituting method by combining dendritic cell multiplication and chemotaxis factor and suicide gene Granted publication date: 20061108 License type: Exclusive License Record date: 20150324 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20061108 |